FDNA Launches Genomics Collaborative® with Multiple Research Partners Globally.
FDNA (www.fdna.com) today announces the launch of the Genomics Collaborative (www.GenomicsCollaborative.com) along with multiple medical research collaborations as part of a new global initiative. Collaborators are using FDNA’s artificial intelligence and deep learning technologies to develop new precision medicine approaches for diagnosing and treating disease, and improving patients’ quality of life.
As a part of the announcement, FDNA is holding an open call for collaboration with patient advocacy groups, clinicians, labs and life sciences stakeholders.
Projects in the Genomics Collaborative are focused on using computational techniques that integrate phenotypic data into the analysis of human genetics. This process, known as “next-generation phenotyping,” or NGP, captures, structures and interprets complex physiological information.
This NGP-generated data can then be used to interpret patient genomic data to help recognize current and future health risks, as well as identify therapeutic targets that will maximize quality and length of life.
To accomplish these goals, FDNA has offered collaborators access to its technologies, which use deep learning neural networks to de-identify and analyze patients’ phenotypic information captured in images, clinical notes, and voice and video recordings to discover correlations between patient data and disease.
As part of the Genomics Collaborative launch, multiple collaborators are announcing projects and support.
Greenwood Genetic Center (GGC) in Greenwood, South Carolina has announced plans to evaluate the use of NGP in identifying and recognizing relationships between certain biomarkers and disease. One planned exploration is of the potential to correlate patterns of facial features with metabolite profiles for various genetic syndromes.
"GGC looks forward to developing new approaches to understanding our patients' health through analysis of metabolites and related genomic data," said Dr. Steve Skinner, Director of GGC. "FDNA's next-generation phenotyping technologies will support GGC in this through advanced capture and analysis of the phenotype, and use of that data to understand the patient's genome as it relates to diagnosis and care."
Dr. Andrea Superti-Furga, Head of Genetic Medicine at Lausanne University Hospital in Switzerland, is working with FDNA in the Genomics Collaborative to analyze correlations between bone structure and genomic data in hopes of yielding discoveries that will support earlier recognition and intervention for patients with skeletal dysplasia disorders.
“We are excited to analyze the characteristics of bone shape and growth for patients affected by one of the more than 400 distinct skeletal dysplasia disorders,” said Superti-Furga. “Next-generation phenotyping technologies have potential to help clinicians recognize underlying genetic or developmental problems earlier in life, allowing for more rapid diagnosis, personalized intervention and improved quality of life.”
Dr. William Dobyns at Seattle Children’s Hospital is contributing clinical data on brain abnormalities to help FDNA determine if such data correlates to genetic variations.
“FDNA has a track record of developing helpful solutions that make a real impact on patient lives,” said Dobyns, who is a medical geneticist and a pediatric neurologist. “I am pleased to help continue that tradition through contributing this data to the Genomics Collaborative.”
Bridge the Gap, an advocacy group in Cypress, Texas, is working with patients, clinicians and FDNA to study SYNGAP1 gene variants related to Fragile X, Angelman, and other related syndromes. The project aims to advance the use of facial analysis and other NGP approaches to help clinicians provide diagnosis and early personalized intervention.
The advocacy group All Things Kabuki is announcing a project to increase recognition of the Kabuki syndrome phenotype and its related gene variants. This will include facial analysis studies to enhance the capabilities already known within Face2Gene.
The successful launch of the Genomics Collaborative is credited to numerous partners, including FDNA’s Centers of Excellence in Research, which began projects with FDNA in 2017 and will continue as part of the Genomics Collaborative.
Current progress can be seen at www.GenomicsCollaborative.com.
“The patient is our greatest asset for the future of precision medicine,” said Ilana Jacqueline, Coordinator of the Genomics Collaborative and Manager of Patient Advocacy for FDNA. “The Genomics Collaborative is making it possible to look at patients in a safe, secure way to help understand how doctors can better diagnose and treat patients, based on their unique traits.”
“We’re interested in working with others to develop technologies that easily capture and analyze that data to help health care providers have all the facts when they are evaluating patients,” Jacqueline continued, “When it comes to having the means to make a faster and more accurate diagnosis, physicians should have every advantage.”
FDNA will work with collaborators to design specific studies and securely capture and analyze patient health data that relates to the proposed research hypotheses. Data will be collected using secure portals and patient questionnaires, when applicable. Collaborators can gather and analyze a variety of data relating to the patient’s symptoms, signs, lifestyle, medical history, and genetic data.
Interested advocacy groups, clinicians, patients and researchers can visit www.genomicscollaborative.com for more information.
About the FDNA Genomics Collaborative
The Genomics Collaborative is an FDNA initiative to accelerate breakthrough in precision medicine using deep learning and artificial intelligence (AI).
Collaborators are using FDNA’s next-generation phenotyping (NGP) technologies, to analyze patient clinical data and next-generation sequencing (NGS) data. The result will be real-time discovery of disease biomarkers, advancement of clinical and molecular technologies, and big genomic data that will increase the ability of genetic testing to provide meaningful answers to difficult health questions.
About Face2Gene and FDNA
FDNA is the developer of Face2Gene* ( www.Face2gene.com ), a suite of phenotyping applications that facilitates comprehensive and precise genetic evaluations. FDNA uses artificial intelligence to detect physiological patterns that reveal disease-causing genetic variations. With the world’s largest network of clinicians, labs and researchers creating one of the fastest growing and most comprehensive genomic databases, FDNA is changing the game for precision medicine.
*Face2Gene is a search and reference tool provided for informational purposes and not intended to replace the clinician’s judgment or experience, nor should it be used to diagnose or treat medical conditions.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 16:05 | Pressemelding
Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the
Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52 | Pressemelding
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal
CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50 | Pressemelding
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation
Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46 | Pressemelding
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c
Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00 | Pressemelding
Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at www.aitheon.com/news) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005269/en/ Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on
ViiV Healthcare Gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe23.3.2018 11:27 | Pressemelding
ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a Positive Opinion recommending marketing authorisation for Juluca (dolutegravir/rilpivirine) for the treatment of HIV infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor. The 2-drug regimen comprises dolutegravir 50mg (ViiV Healthcare) and rilpivirine 25mg (Janssen Sciences Ireland UC). Deborah Waterhouse, Chief Executive Officer at ViiV Healthcare commented: “Today is an important milestone for people living with HIV in Europe. It takes us a step closer to offering the first, single-pill, 2-drug regi